ArticlePsycho-oncology2025
Acute Change in Perceived Cognitive Performance Across Different Age Groups Following First Chemotherapy Infusion in Female Patients With Breast Cancer.
Article in Psycho-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparing chemotherapy-induced nausea and vomiting between young adult vs non-young adult cancer patients.JNCI cancer spectrum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundCancer-related cognitive impairment (CRCI) is frequently reported by women with breast cancer after chemotherapy. Yet, the acute effects of a single infusion on perceived cognition remain understudied, especially across different age groups.
aimsThis study assessed acute changes in perceived cognition following the first chemotherapy infusion in young (< 40 years), middle-aged (40-64 years), and older adults (≥ 65 years) with breast cancer and identified baseline risk factors associated with worsened CRCI in these age groups.
methodsChemotherapy-naïve women with breast cancer scheduled for intravenous chemotherapy completed PROMIS Cognitive Abilities 4a and Cognitive Function 8a assessments before and 5 days post-infusion. Clinically significant CRCI was defined as T-scores ≤ 45. Paired t-tests, chi-square tests, and residualized regression models (univariate and multivariable) were used to evaluate changes in cognition and associated risk factors.
resultsAmong all participants (N = 528; 85 young, 329 middle-aged, 114 older), perceived cognitive performance significantly declined, and the prevalence of CRCI increased across all three age groups (FDR adjusted p-values < 0.05). Among middle-aged patients, the White race (p = 0.011) and a college degree (p = 0.001) were associated with worsened cognitive function, while a college degree (p = 0.009) and sleep disturbance (p = 0.012) were linked to worsened cognitive ability. In older adults, depressive symptoms were associated with worsened cognitive function (p = 0.017) and cognitive ability (p = 0.011).
conclusionsCognitive impairment develops acutely after the first chemotherapy infusion across all age groups, with risk factors varying by age. Age-specific interventions are needed to address early cognitive decline in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.